Distinct action of aranidipine and its active metabolite on renal arterioles, with special reference to renal protection

Akira Nakamura, Koichi Hayashi, Keiji Fujiwara, Yuri Ozawa, Masanori Honda, Takao Saruta

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Aranidipine, a newly developed calcium antagonist, possesses unique pharmacologic characteristics in that its metabolite (M-1) still has antihypertensive action. We examined the effects of both agents on renal microcirculation using the isolated perfused hydronephrotic rat kidney. During norepinephrine-induced constriction, the addition of aranidipine dilated both afferent and efferent arterioles in a dose-dependent manner; at 10-6 M, 83 ± 6% and 90 ± 6% reversal, respectively. In contrast, its active metabolite exerted dilator action predominantly on the afferent arteriole (79 ± 4% vs. 44 ± 17% at 10-6 M for afferent and efferent arterioles, respectively). We further examined the long-term (8 weeks) effect of these agents on the development of renal injury in salt-loaded subtotally nephrectomized spontaneously hypertensive rats. Both aranidipine and M-1 reduced blood pressure by a similar magnitude. The decreases in proteinuria were observed in the aranidipine-treated group at weeks 6, 8, and 10, whereas in the M-1 group, significant reduction was attained only at week 6. Histopathologic examination revealed that both treatments improved glomerular and arteriolar sclerosis. Glomerular sclerosis, however, was less pronounced in the aranidipine-treated group than in the M-1 group. In conclusion, aranidipine has dilator action on both arterioles, whereas M-1 caused predominant dilation of afferent arterioles. Such metabolic changes may constitute a determinant of efferent arteriolar action of the calcium antagonist.

Original languageEnglish
Pages (from-to)942-948
Number of pages7
JournalJournal of Cardiovascular Pharmacology
Volume35
Issue number6
DOIs
Publication statusPublished - 2000

Fingerprint

Arterioles
Kidney
Arteriolosclerosis
Renal Agents
Calcium
Sclerosis
Inbred SHR Rats
Microcirculation
Proteinuria
Constriction
Antihypertensive Agents
aranidipine
Dilatation
Norepinephrine
Salts
Blood Pressure
Wounds and Injuries

Keywords

  • Afferent arterioles
  • Aranidipine
  • Calcium antagonists
  • Efferent arterioles
  • Proteinuria
  • Renal injury

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Cite this

Distinct action of aranidipine and its active metabolite on renal arterioles, with special reference to renal protection. / Nakamura, Akira; Hayashi, Koichi; Fujiwara, Keiji; Ozawa, Yuri; Honda, Masanori; Saruta, Takao.

In: Journal of Cardiovascular Pharmacology, Vol. 35, No. 6, 2000, p. 942-948.

Research output: Contribution to journalArticle

Nakamura, Akira ; Hayashi, Koichi ; Fujiwara, Keiji ; Ozawa, Yuri ; Honda, Masanori ; Saruta, Takao. / Distinct action of aranidipine and its active metabolite on renal arterioles, with special reference to renal protection. In: Journal of Cardiovascular Pharmacology. 2000 ; Vol. 35, No. 6. pp. 942-948.
@article{b61480beaf7a4edbb39b7c4cdfdd5a10,
title = "Distinct action of aranidipine and its active metabolite on renal arterioles, with special reference to renal protection",
abstract = "Aranidipine, a newly developed calcium antagonist, possesses unique pharmacologic characteristics in that its metabolite (M-1) still has antihypertensive action. We examined the effects of both agents on renal microcirculation using the isolated perfused hydronephrotic rat kidney. During norepinephrine-induced constriction, the addition of aranidipine dilated both afferent and efferent arterioles in a dose-dependent manner; at 10-6 M, 83 ± 6{\%} and 90 ± 6{\%} reversal, respectively. In contrast, its active metabolite exerted dilator action predominantly on the afferent arteriole (79 ± 4{\%} vs. 44 ± 17{\%} at 10-6 M for afferent and efferent arterioles, respectively). We further examined the long-term (8 weeks) effect of these agents on the development of renal injury in salt-loaded subtotally nephrectomized spontaneously hypertensive rats. Both aranidipine and M-1 reduced blood pressure by a similar magnitude. The decreases in proteinuria were observed in the aranidipine-treated group at weeks 6, 8, and 10, whereas in the M-1 group, significant reduction was attained only at week 6. Histopathologic examination revealed that both treatments improved glomerular and arteriolar sclerosis. Glomerular sclerosis, however, was less pronounced in the aranidipine-treated group than in the M-1 group. In conclusion, aranidipine has dilator action on both arterioles, whereas M-1 caused predominant dilation of afferent arterioles. Such metabolic changes may constitute a determinant of efferent arteriolar action of the calcium antagonist.",
keywords = "Afferent arterioles, Aranidipine, Calcium antagonists, Efferent arterioles, Proteinuria, Renal injury",
author = "Akira Nakamura and Koichi Hayashi and Keiji Fujiwara and Yuri Ozawa and Masanori Honda and Takao Saruta",
year = "2000",
doi = "10.1097/00005344-200006000-00018",
language = "English",
volume = "35",
pages = "942--948",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Distinct action of aranidipine and its active metabolite on renal arterioles, with special reference to renal protection

AU - Nakamura, Akira

AU - Hayashi, Koichi

AU - Fujiwara, Keiji

AU - Ozawa, Yuri

AU - Honda, Masanori

AU - Saruta, Takao

PY - 2000

Y1 - 2000

N2 - Aranidipine, a newly developed calcium antagonist, possesses unique pharmacologic characteristics in that its metabolite (M-1) still has antihypertensive action. We examined the effects of both agents on renal microcirculation using the isolated perfused hydronephrotic rat kidney. During norepinephrine-induced constriction, the addition of aranidipine dilated both afferent and efferent arterioles in a dose-dependent manner; at 10-6 M, 83 ± 6% and 90 ± 6% reversal, respectively. In contrast, its active metabolite exerted dilator action predominantly on the afferent arteriole (79 ± 4% vs. 44 ± 17% at 10-6 M for afferent and efferent arterioles, respectively). We further examined the long-term (8 weeks) effect of these agents on the development of renal injury in salt-loaded subtotally nephrectomized spontaneously hypertensive rats. Both aranidipine and M-1 reduced blood pressure by a similar magnitude. The decreases in proteinuria were observed in the aranidipine-treated group at weeks 6, 8, and 10, whereas in the M-1 group, significant reduction was attained only at week 6. Histopathologic examination revealed that both treatments improved glomerular and arteriolar sclerosis. Glomerular sclerosis, however, was less pronounced in the aranidipine-treated group than in the M-1 group. In conclusion, aranidipine has dilator action on both arterioles, whereas M-1 caused predominant dilation of afferent arterioles. Such metabolic changes may constitute a determinant of efferent arteriolar action of the calcium antagonist.

AB - Aranidipine, a newly developed calcium antagonist, possesses unique pharmacologic characteristics in that its metabolite (M-1) still has antihypertensive action. We examined the effects of both agents on renal microcirculation using the isolated perfused hydronephrotic rat kidney. During norepinephrine-induced constriction, the addition of aranidipine dilated both afferent and efferent arterioles in a dose-dependent manner; at 10-6 M, 83 ± 6% and 90 ± 6% reversal, respectively. In contrast, its active metabolite exerted dilator action predominantly on the afferent arteriole (79 ± 4% vs. 44 ± 17% at 10-6 M for afferent and efferent arterioles, respectively). We further examined the long-term (8 weeks) effect of these agents on the development of renal injury in salt-loaded subtotally nephrectomized spontaneously hypertensive rats. Both aranidipine and M-1 reduced blood pressure by a similar magnitude. The decreases in proteinuria were observed in the aranidipine-treated group at weeks 6, 8, and 10, whereas in the M-1 group, significant reduction was attained only at week 6. Histopathologic examination revealed that both treatments improved glomerular and arteriolar sclerosis. Glomerular sclerosis, however, was less pronounced in the aranidipine-treated group than in the M-1 group. In conclusion, aranidipine has dilator action on both arterioles, whereas M-1 caused predominant dilation of afferent arterioles. Such metabolic changes may constitute a determinant of efferent arteriolar action of the calcium antagonist.

KW - Afferent arterioles

KW - Aranidipine

KW - Calcium antagonists

KW - Efferent arterioles

KW - Proteinuria

KW - Renal injury

UR - http://www.scopus.com/inward/record.url?scp=0034044952&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034044952&partnerID=8YFLogxK

U2 - 10.1097/00005344-200006000-00018

DO - 10.1097/00005344-200006000-00018

M3 - Article

C2 - 10836731

AN - SCOPUS:0034044952

VL - 35

SP - 942

EP - 948

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - 6

ER -